Most Viewed Trastuzumab Current Events | Trastuzumab News
|
|
|
Sort By:
Relevance | Date |
Primrose oil component cuts levels of cancer-causing gene Her-2/neu
Gamma-linolenic acid (GLA), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers. view more (2005-11-02)
New Herceptin results confirm impressive reduction in risk of cancer returning
New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer. view more (2005-09-14)
Cancerous vs. healthy cells: Researchers identify the road to success
Conventional cancer treatments are generally effective in wiping out tumor cells, but in the process they also may kill healthy cells. view more (2006-04-10)
Herceptin treatment lowers recurrence rate in early breast cancer
The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy. view more (2005-10-20)
Mayo Clinic reports breakthrough treatment for breast cancer
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive... view more... (2005-10-20)
Herceptin effective in breast cancer cells with low HER-2 levels
Northwestern University and Evanston Northwestern Healthcare researchers have discovered that the monoclonal antibody Herceptin (trastuzumab) used in combination with certain cancer chemotherapies effectively treats breast cancer tumors that produce low or undetectable amounts of the HER-2 oncogene but overexpress the growth factor heregulin... view more... (2006-08-11)
Results good for HER-2 positive breast cancer patients using trastuzumab
Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug. view more (2006-06-06)
Fresh use of targeted therapy advances treatment of early HER2-positive breast cancer
The news that the world's first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer "highlights a truly significant advance in the management of breast cancer," says Edith Perez, M.D., director of Mayo Clinic's Breast Clinic in Jacksonville, Fla. view more (2006-11-20)
Headlines about Herceptin show equality of access to costly drugs must be tackled
The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in this week's BMJ. view more (2005-11-04)
Analysis of breast-cancer gene role offers promising target
Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients. view more (2006-10-31)
Study finds cardiac toxicity rates high with herceptin use
The first study to look at "real world" use of Herceptin in advanced breast cancer patients found a higher incidence of cardiac toxicity - 28 percent of patients treated - than clinical trials of the drug have reported to date, but also concluded that the majority of this heart damage could be reversed with treatment. view more (2006-08-15)
New role for sugars: Research shows connections between sugar modifications in cells and cancer
In a ground-breaking study published in the top journal, Cell, Dr. James Dennis, senior investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, has discovered a new role for sugars on proteins. view more (2007-04-06)
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use. view more (2008-04-17)
Study suggests newer breast cancer drug may protect heart
By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs. view more (2007-06-11)
Herceptin does not increase heart failure in patients long-term
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31. view more (2007-06-04)
Analysis confirms benefits of combining trastuzumab and chemotherapy
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer. view more (2007-07-09)
Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients. view more (2004-01-08)
Breast cancer subtypes linked to survival from secondary brain tumors
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. view more (2008-02-28)
A search for protection against chemotherapy cardiotoxicity
Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. view more (2007-12-21)
Reining in cancer - first laboratory study to show that combining novel targeted therapiesmay keep cancer cells under control
A team of Italian researchers has demonstrated in the laboratory for the first time that combining two of the newest anti-cancer targeted agents may produce a powerful new combination against breast cancer - and possibly many other cancers as well. Their findings are reported (Thursday 24 January) in the journal Annals of Oncology.* They found... view more... (2002-01-21)
|
|
|
|
Sort By:
Relevance | Date |
|
